Sana Biotechnology Receives FDA Fast Track Designation for SC291 in Treatment of Relapsed/Refractory Systemic Lupus Erythematosus
Sana Biotechnology's SC291 receives FDA Fast Track designation for treating relapsed/refractory systemic lupus erythematosus, with initial data expected in 2025.Quiver AI SummarySana Biotechnology, Inc....
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...
Flagship Pioneering Named to Fortune's 2023 "Change the World" List
/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...